Tags

Type your tag names separated by a space and hit enter

Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin.
J Gastroenterol Hepatol. 2015 May; 30(5):858-65.JG

Abstract

BACKGROUND AND AIM

The anti-inflammatory effects of liquiritigenin, a major flavonoid isolated from Glycyrrhizae uralensis, have been reported in many inflammation models. However, its protective effects have not been reported in a colitis model. This study investigated the anti-inflammatory effect and mechanism of liquiritigenin for trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice.

METHODS

Male mice imprinting control regions (ICR) were randomly divided into five groups: normal, TNBS-induced colitis, colitis treated with liquiritigenin at low dose (10 mg/kg) and high dose (20 mg/kg), or mesalazine (10 mg/kg). TNBS colitis induction was performed except for in the normal group, and they were treated with liquiritigenin or mesalazine except control group. The treatment effect was measured after three days treatment, by body weight, colon length, macroscopic score, histological score, levels of cytokines (tumor necrosis factor-α, interleukin [IL]-1β, IL-6, and IL-10) in colon tissue as well as the nuclear factor kappa-light-chain-enhancer pathway of activated B cells (NF-κB) activation.

RESULTS

Mice treated with high-dose liquiritigenin showed significant body weight gain, inhibition of colon shortening, protective effect on histological damages, and myeloperoxidase activity of colon tissue compared with the control group. Furthermore, mice treated with high-dose liquiritigenin experienced significantly suppressed tumor necrosis factor-α, IL-1β, and IL-6 as well as enhanced IL-10 expression (all P < 0.05). High-dose liquiritigenin treatment group showed significant decreases in TNBS-induced phosphorylation of IKKβ, p65, and IκB-α.

CONCLUSION

Liquiritigenin may ameliorate TNBS-induced colitis in mice by suppressing expression of pro-inflammatory cytokines through NF-κB pathway.

Authors+Show Affiliations

Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25311527

Citation

Min, Joon Ki, et al. "Amelioration of Trinitrobenzene Sulfonic Acid-induced Colitis in Mice By Liquiritigenin." Journal of Gastroenterology and Hepatology, vol. 30, no. 5, 2015, pp. 858-65.
Min JK, Lee CH, Jang SE, et al. Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin. J Gastroenterol Hepatol. 2015;30(5):858-65.
Min, J. K., Lee, C. H., Jang, S. E., Park, J. W., Lim, S. J., Kim, D. H., Bae, H., Kim, H. J., & Cha, J. M. (2015). Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin. Journal of Gastroenterology and Hepatology, 30(5), 858-65. https://doi.org/10.1111/jgh.12812
Min JK, et al. Amelioration of Trinitrobenzene Sulfonic Acid-induced Colitis in Mice By Liquiritigenin. J Gastroenterol Hepatol. 2015;30(5):858-65. PubMed PMID: 25311527.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin. AU - Min,Joon Ki, AU - Lee,Chi Hoon, AU - Jang,Se-Eun, AU - Park,Jae-Woo, AU - Lim,Sung-Jig, AU - Kim,Dong-Hyun, AU - Bae,Hyunsu, AU - Kim,Hyo-Jong, AU - Cha,Jae Myung, PY - 2014/10/02/accepted PY - 2014/10/15/entrez PY - 2014/10/15/pubmed PY - 2016/1/15/medline KW - NF-κB KW - colitis KW - colon KW - inflammation KW - liquiritigenin SP - 858 EP - 65 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 30 IS - 5 N2 - BACKGROUND AND AIM: The anti-inflammatory effects of liquiritigenin, a major flavonoid isolated from Glycyrrhizae uralensis, have been reported in many inflammation models. However, its protective effects have not been reported in a colitis model. This study investigated the anti-inflammatory effect and mechanism of liquiritigenin for trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. METHODS: Male mice imprinting control regions (ICR) were randomly divided into five groups: normal, TNBS-induced colitis, colitis treated with liquiritigenin at low dose (10 mg/kg) and high dose (20 mg/kg), or mesalazine (10 mg/kg). TNBS colitis induction was performed except for in the normal group, and they were treated with liquiritigenin or mesalazine except control group. The treatment effect was measured after three days treatment, by body weight, colon length, macroscopic score, histological score, levels of cytokines (tumor necrosis factor-α, interleukin [IL]-1β, IL-6, and IL-10) in colon tissue as well as the nuclear factor kappa-light-chain-enhancer pathway of activated B cells (NF-κB) activation. RESULTS: Mice treated with high-dose liquiritigenin showed significant body weight gain, inhibition of colon shortening, protective effect on histological damages, and myeloperoxidase activity of colon tissue compared with the control group. Furthermore, mice treated with high-dose liquiritigenin experienced significantly suppressed tumor necrosis factor-α, IL-1β, and IL-6 as well as enhanced IL-10 expression (all P < 0.05). High-dose liquiritigenin treatment group showed significant decreases in TNBS-induced phosphorylation of IKKβ, p65, and IκB-α. CONCLUSION: Liquiritigenin may ameliorate TNBS-induced colitis in mice by suppressing expression of pro-inflammatory cytokines through NF-κB pathway. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/25311527/Amelioration_of_trinitrobenzene_sulfonic_acid_induced_colitis_in_mice_by_liquiritigenin_ L2 - https://doi.org/10.1111/jgh.12812 DB - PRIME DP - Unbound Medicine ER -